These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8091399)

  • 1. Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation.
    Chen LY; Mehta JL
    Thromb Res; 1994 Jun; 74(6):555-63. PubMed ID: 8091399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator.
    Penny WF; Ware JA
    Blood; 1992 Jan; 79(1):91-8. PubMed ID: 1530814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
    Mehta JL; Chen L; Nichols WW; Johannesen M; Bregengård C; Hedner U; Saldeen TG
    J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nature of interactions between tissue-type plasminogen activator and platelets.
    Torr SR; Winters KJ; Santoro SA; Sobel BE
    Thromb Res; 1990 Jul; 59(2):279-93. PubMed ID: 2146766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of staphylokinase on platelet aggregation.
    Suehiro A; Oura Y; Ueda M; Kakishita E
    Thromb Haemost; 1993 Nov; 70(5):834-7. PubMed ID: 7510426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the sites of plasminogen molecule which are responsible for inhibitory effect of Lys-plasminogen on platelet aggregation.
    Roka-Moya YM; Zhernossekov DD; Yusova EI; Kapustianenko LG; Grinenko TV
    Ukr Biochem J; 2014; 86(5):82-8. PubMed ID: 25816591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
    Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
    Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.
    Gouin I; Lecompte T; Morel MC; Lebrazi J; Modderman PW; Kaplan C; Samama MM
    Circulation; 1992 Mar; 85(3):935-41. PubMed ID: 1531623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of plasmin-induced platelet aggregation.
    Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
    Aronson DL; Chang P; Kessler CM
    Circulation; 1992 May; 85(5):1706-12. PubMed ID: 1533349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
    Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
    Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiated thrombolysis in a Chandler system using rtPA and lys-plasminogen.
    Ljungberg J; Hedner U
    Thromb Res; 1989 Mar; 53(6):569-76. PubMed ID: 2499945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activity.
    Torr SR; Eisenberg PR; Sobel BE
    Thromb Res; 1991 Nov; 64(4):435-44. PubMed ID: 1724101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins.
    Rudd MA; George D; Amarante P; Vaughan DE; Loscalzo J
    Circ Res; 1990 Nov; 67(5):1175-81. PubMed ID: 2146037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heparan sulfate analogue or other sulfated polysaccharides on the activation of plasminogen by t-PA or u-PA.
    Takada Y; Urano T; Takada A
    Thromb Res; 1994 Mar; 73(5):301-11. PubMed ID: 8016815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.